Clinical Trials · NCT05205928
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Enrollment
- 28
- Start date
- Oct 2022
- Locations
- 1 site, Canada
- Primary endpoint
- Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo)